GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Publisher
Person/Organisation
Language
Years
FID
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents
    Elsevier BV ; 2004
    In:  Bioorganic & Medicinal Chemistry Letters Vol. 14, No. 18 ( 2004-9), p. 4751-4754
    Details
    In: Bioorganic & Medicinal Chemistry Letters, Elsevier BV, Vol. 14, No. 18 ( 2004-9), p. 4751-4754
    Type of Medium: Online Resource
    ISSN: 0960-894X
    URL: Article
    DOI: 10.1016/j.bmcl.2004.06.083
    RVK:
    VA 2620
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2004
    detail.hit.zdb_id: 1501505-1
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract 3991: The genetic variants of growth factor-related genes associate with the prognosis of patients with advanced esophageal squamous cell carcinoma .
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3991-3991
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3991-3991
    Abstract: PURPOSE: To investigate the association between the genetic polymorphisms of growth factor-related genes and the prognosis of patients with advanced esophageal squamous cell carcinoma (ESCC). PATIENTS AND METHODS: A total of 336 ESCC patients with advanced tumor stages (stage 2b+3+4) were enrolled in the study. These subjects were randomly assigned to a training set (n=95) and a replication set (n=241).The genotypes of candidate single nucleotide polymorphism (SNPs) were analyzed using iPLEX Gold technology from the genomic DNA of peripheral leukocytes, and were correlated with the clinical outcome of patients in training, replication, and combined groups. Serum levels of growth factors were examined by enzyme-link immunosorbent assay (ELISA). RESULTS: In training group, the genotyping of 16 candidate SNPs was successfully performed. Seven SNPs, rs4444903, rs2010963, rs2272037, rs713646, rs3025039, rs3025040, rs2016347, significant or borderline significant correlated with mortality or disease progression and were further evaluated in an independent replication group. In replication group, GG of rs4444903 at EGF gene and CC of rs2010903 at VEGF showed unfavorable trend for the mortality (P=0.286 for rs4444903; P=0.215 for rs2010963). These 2 SNPs showed significant effects on overall survival of the patients in combing group (GG vs. AA, adjusted [HR] = 1.29, 95% CI=1.01-1.66, P=0.045 for rs4444903; CC vs. GG, adjusted [HR] = 1.53, 95% CI=1.07-2.18, P=0.020 for rs2010963). Meanwhile, GA genotype of rs2272037at IGF1R gene also show unfavorable trend among all subjects (GA vs. GG, [HR] = 1.24, 95% CI=0.96-1.60, P=0.108). Combing these 3 SNPs, patients with 3 unfavorable genotypes showed 2-fold risk for mortality compared to patients without any of the unfavorable genotypes (accumulated unfavorable genotypes 3 vs. 0, [HR] = 2.00, 95% CI=1.10-3.64, P=0.023). Additionally, GG genotype of EGF_rs4444903 correlated with increase serum levels of EGF in patients with advanced ESCC. Finally, both EGF and VEGF expression levels significant associated with the mortality of patients. CONCLUSION: The genetic variants in growth factor-related can serve as prognostic predictors of the patients with advanced ESCC, and thus provide more information for the personalized therapies for the patients with ESCC. Citation Format: Jang-Ming Lee, Pei-Wen Yang, Ya-Chuan Huang, Min-Shu Hsieh, Ching-Yueh Hsieh, Pei-Ming Huang, Hsao-Hsun Hsu, Jin-Shing Chen, Shuenn-Wen Kuo. The genetic variants of growth factor-related genes associate with the prognosis of patients with advanced esophageal squamous cell carcinoma . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3991. doi:10.1158/1538-7445.AM2013-3991
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2013-3991
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Epigenetic profiling of the H19 differentially methylated region and comprehensive whole genome array‐based analysis in Silver–Russell syndrome
    Wiley ; 2010
    In:  American Journal of Medical Genetics Part A Vol. 152A, No. 10 ( 2010-10), p. 2521-2528
    Details
    In: American Journal of Medical Genetics Part A, Wiley, Vol. 152A, No. 10 ( 2010-10), p. 2521-2528
    Abstract: Silver–Russell syndrome (SRS) is a clinically and genetically heterogeneous congenital disorder characterized by severe growth retardation. Hypomethylation of the differentially methylated region (DMR) of the H19 gene and uniparental disomy of maternal chromosome 7 is present in ∼45% of the patients with SRS so more than half of these patients have no known genetic etiology. We combined several molecular technologies including multiplex methylation polymerase chain reaction, methylation‐sensitive multiple ligation probe‐dependent amplification, and methylation‐sensitive high‐resolution melting to assess the epigenetic status of 34 patients with SRS. Additionally, we applied a whole genome strategy to detect copy number changes and loss of heterozygosity. Thirteen patients (38.2%) had hypomethylation of the DMR of the H19 gene and none had uniparental disomy of maternal chromosome 7. The whole genome arrays identified five patients (14.7%) with microdeletions on chromosomes 1q23q24.3, 7p15.3, 13q31.3, 14q32.31, and 15q26.2qter, respectively. The overall mutation detection rate was 52.9% by the epigenetic study and the whole genome strategy. Although epimutation may be the major cause of SRS and can be identified by multiplex methylation polymerase chain reaction, the whole genome approach also provides information on the etiology of SRS. If no epimutation is identified in the patients with typical SRS, microdeletions should be suspected. © 2010 Wiley‐Liss, Inc.
    Type of Medium: Online Resource
    ISSN: 1552-4825 , 1552-4833
    URL: Issue
    URL: Article
    DOI: 10.1002/ajmg.a.v152a:10
    DOI: 10.1002/ajmg.a.33629
    Language: English
    Publisher: Wiley
    Publication Date: 2010
    detail.hit.zdb_id: 1493479-6
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Different Impacts of α- and β-Blockers in Neurogenic Hypertension Produced by Brainstem Lesions in Rat
    Ovid Technologies (Wolters Kluwer Health) ; 2014
    In:  Anesthesiology Vol. 120, No. 5 ( 2014-05-01), p. 1192-1204
    Details
    In: Anesthesiology, Ovid Technologies (Wolters Kluwer Health), Vol. 120, No. 5 ( 2014-05-01), p. 1192-1204
    Abstract: Bilateral lesions of nucleus tractus solitarii in rat result in acute hypertension, pulmonary edema, and death within hours. The hypertension results from excessive catecholamine release. Catecholamine can activate connexin43 to regulate cell death. There is no study investigating the cardiopulmonary impacts of different adrenergic blockers and apoptosis mechanism in rat model. Methods: The authors microinjected 6-hydroxydopamine into nucleus tractus solitarii of the rat (n = 8 per group) and evaluated the cardiopulmonary changes after treatment with different concentrations of α1-blockers, α2-blockers, β-blockers, and α-agonists. Results: In the rat model, the authors found that prazosin (0.15 mg/kg) treatment could preserve cardiac output and reverse neutrophil infiltrations in lungs and lead to prevent pulmonary hemorrhagic edema. The time-dependent increases in connexin43 and terminal deoxynucleotidyl transferase dUTP nick end labeling–positive cells induced by 6-hydroxydopamine lesions were decreased after prazosin treatment (terminal deoxynucleotidyl transferase dUTP nick end labeling–positive cells at 6 h: 64.01 ± 2.41% vs. 24.47 ± 3.10%; mean ± SD, P & lt; 0.001, in heart, and 80.83 ± 2.52% vs. 2.60 ± 1.03%, P & lt; 0.001, in lung). However, propranolol caused further compromise of the already impaired cardiac output with consequence of rapid death. Phenylephrine enhanced the phenotype in the link between connexin43 expressions and terminal deoxynucleotidyl transferase dUTP nick end labeling–positive cells but not yohimbine. Connexin43 expressions and terminal deoxynucleotidyl transferase dUTP nick end labeling–positive cells were more decreased with prazosin (0.15 and 0.3 mg/kg) than that with prazosin (0.05 mg/kg) treatment. Conclusions: α1-Receptors are the keystones of the phenotype. In some brainstem encephalitis and brain injury with nucleus tractus solitarii involvement, early α1-receptor blockade treatment may prevent acute death from tissue apoptosis. α-Blockers can also decrease cerebral perfusion pressure, and further studies are needed in translation to brain injury with increased intracranial pressure.
    Type of Medium: Online Resource
    ISSN: 0003-3022
    URL: Article
    DOI: 10.1097/ALN.0000000000000218
    RVK:
    XA 22600
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2014
    detail.hit.zdb_id: 2016092-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Novel Anti-Viral Properties of the Herbal Extract of Davallia mariesii against Influenza A Virus
    MDPI AG ; 2024
    In:  Viruses Vol. 16, No. 4 ( 2024-03-28), p. 523-
    Details
    In: Viruses, MDPI AG, Vol. 16, No. 4 ( 2024-03-28), p. 523-
    Abstract: Gu-Sui-Bu, the dried rhizome of Davallia mariesii, is a traditional Chinese herbal remedy with a significant history of treating osteoporosis and inflammatory conditions. However, its potential as an anti-influenza agent and its underlying mechanisms of action remain unexplored. To obtain a more potent extract from D. mariesii and gain insights into its mechanism of action against influenza A virus (IAV), we utilized a partitioning process involving organic solvents and water, resulting in the isolation of butanolic subfractions of the D. mariesii extract (DMBE). DMBE exhibited a broad anti-viral spectrum, effectively inhibiting IAV, with an EC50 of 24.32 ± 6.19 µg/mL and a selectivity index of 6.05. We subsequently conducted a series of in vitro assays to evaluate the antiviral effects of DMBE and to uncover its mechanisms of action. DMBE was found to inhibit IAV during the early stages of infection by hindering the attachment of the virus onto and its penetration into host cells. Importantly, DMBE was observed to hinder IAV-mediated cell–cell fusion. It also inhibited neuraminidase activity, plaque size, and the expression levels of phospho-AKT. In summary, this study provides evidence for the effectiveness of D. mariesii as a complementary and alternative herbal remedy against IAV. Specifically, our data highlight DMBE’s capabilities in inhibiting viral entry and the release of virions.
    Type of Medium: Online Resource
    ISSN: 1999-4915
    URL: Article
    DOI: 10.3390/v16040523
    Language: English
    Publisher: MDPI AG
    Publication Date: 2024
    detail.hit.zdb_id: 2516098-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo
    Elsevier BV ; 2021
    In:  Biochemical Pharmacology Vol. 190 ( 2021-08), p. 114596-
    Details
    In: Biochemical Pharmacology, Elsevier BV, Vol. 190 ( 2021-08), p. 114596-
    Type of Medium: Online Resource
    ISSN: 0006-2952
    URL: Article
    DOI: 10.1016/j.bcp.2021.114596
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 1496199-4
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance–Associated Protein 2 and Breast Cancer Resistance Protein
    Elsevier BV ; 2016
    In:  Journal of Pharmaceutical Sciences Vol. 105, No. 1 ( 2016-01), p. 343-349
    Details
    In: Journal of Pharmaceutical Sciences, Elsevier BV, Vol. 105, No. 1 ( 2016-01), p. 343-349
    Type of Medium: Online Resource
    ISSN: 0022-3549
    URL: Article
    DOI: 10.1016/j.xphs.2015.11.031
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2016
    detail.hit.zdb_id: 1491821-3
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Abstract LB209: An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells
    American Association for Cancer Research (AACR) ; 2023
    In:  Cancer Research Vol. 83, No. 8_Supplement ( 2023-04-14), p. LB209-LB209
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 8_Supplement ( 2023-04-14), p. LB209-LB209
    Abstract: Introduction: Multiple myeloma (MM) is a neoplastic malignancy characterized by the abnormal proliferation of plasma cells with excessive antibody production in the bone marrow. It accounts for approximately 1.8% of all new cancer cases and 2.1% of cancer deaths in the United States and occurs most frequently among older adults (age & gt; 75). While there are a number of treatments with high response rates, MM relapses frequently within a few years and is considered incurable. Herein, experimental studies and results of a new therapeutic agent under development, TE-1146, are reported. TE-1146 is an antibody drug conjugate (ADC) composed of two therapeutic agents already in use in MM, namely, an anti-CD38 antibody, daratumumab (Dara), and lenalidomide (Lena). Method: TE-1146 is designed by employing “HIDAR” technology platform, which enables the preparation of homogeneous ADCs with high DAR (drug to antibody ratio). In the TE-1146 molecules, the Fab is replaced by scFv and a cysteine-containing Zn2+-binding motif is engineered at the C-termini of the H chains. Lena molecules are assembled into drug bundles containing 3 Lena molecules and a maleimide group. Two drug bundles are conjugated site-specifically to the Zn2+-activated SH groups of the reconfigured antibody molecule, creating an ADC with DAR of 6. TE-1146 was investigated for cytolytic effects against human MM cell lines H929 in cell cultures in vitro and transplanted H929 tumor in NOD-SCID mice in vivo, in comparison with Dara, Lena, and their combination. Results: In human plasma, TE-1146 has stability comparable with Dara, and the Lena molecules in the drug bundles remain conjugated. In cultures of H929 cells, TE-1146 caused the lysis of H929 cells at least 100 times more effectively than Dara, Lena, and Dara/Lena combination, based on IC50 comparison. It was shown that H929 cells internalized and degraded TE-1146 and freed Lena. In NOD-SCID mice, the subcutaneously transplanted H929 cells were allowed to grow into solid tumors in 14 days, and TE-1146 and other agents for comparison were administered intraperitoneally. It was found that one single dose of TE-1146 at 20 nmol/kg (conjugated with Lena at 120 nmol/kg) could retard the growth of the transplanted tumor and ultimately eliminate the tumor over 28-42 days, while the combination of one dose Dara at 20-80 nmol/kg and Lena of 46 μmol/kg given daily could not eliminate the tumor. The amount of Lena used in the combination treatment over a 28-day course is 10,700 times that of Lena in TE-1146. Conclusion: Lenalidomide is extremely powerful in killing multiple myeloma cells if brought into the MM cells. It is estimated that a very minute amount, probably less than 0.01%, of intraperitoneally injected lenalidomide gets into the transplanted MM tumor in the mouse model. TE-1146 may be a more effective and less toxic drug than Daratumumab/Lenalidomide combination in treating patients with hard-to-treat MM. Citation Format: Yueh-Hsiang Yu, Ming-Yu Hsieh, Pei-Wen Wu, Hui-Ju Lee, Pei-Hsuan Lin, Carmay Lim, Hsing-Mao Chu, Tse Wen Chang. An ADC composed of daratumumab and lenalidomide is extremely powerful in killing multiple myeloma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB209.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2023-LB209
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    The Survival Impact of XPA and XPC Genetic Polymorphisms on Patients with Esophageal Squamous Cell Carcinoma
    Springer Science and Business Media LLC ; 2013
    In:  Annals of Surgical Oncology Vol. 20, No. 2 ( 2013-2), p. 562-571
    Details
    In: Annals of Surgical Oncology, Springer Science and Business Media LLC, Vol. 20, No. 2 ( 2013-2), p. 562-571
    Type of Medium: Online Resource
    ISSN: 1068-9265 , 1534-4681
    URL: Article
    DOI: 10.1245/s10434-012-2622-x
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2013
    detail.hit.zdb_id: 2074021-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Abstract 4365: A cellular model for investigation of circulating tumor cells and identification of therapeutic target and regimen
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 4365-4365
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 4365-4365
    Abstract: Tumor cells disseminating into circulatory system is crucial for cancer metastasis during cancer progression and surgical operation in removing tumor mass. Due to technical hurdles, it is not yet available to culture and propagate circulating tumor cells derived from cancer patients. Not yet any model system has been established to investigate the cellular and molecular changes associate with the entry of primary tumor cells into bloodstream. In this study, genetically modified C6 glioma cells (C6-LG) that elicit high procoagulant activity and express luciferase/GFP reporter gene were used for xenograft injection into nude mice to establish a metastatic model. Two C6-derived sublines, C6-lung and C6-blood, were isolated and established from the cells that colonized at lung tissue and from blood circulation, respectively. Cellular analyses revealed that C6-lung and C6-blood had differential cell cycle distribution, cell growth rate, migration and metastatic potential. Microarray analyses also revealed differential gene expression signatures between these two sublines. Nevertheless, podoplanin was up-regulated in both cell lines when compared to the parental C6-LG. Consistent with these observations, C6-lung and C6-blood activated platelet and induced platelet aggregation that is closely associated with their in vivo metastatic potential as revealed by gene knockdown analysis. Using these C6-sublines as the cellular screening platform, we have identified a novel compound designated as CGU-07 that elicited inhibitory activity in cancer cell-induced platelet aggregation. In conclusion, circulating and primary tumor cells have both common and distinguished cellular and molecular profiles. Targeting on the common molecular signature such as podoplanin raises the hope to further application of its therapeutic use in the prevention and treatment of tumor metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4365. doi:1538-7445.AM2012-4365
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2012-4365
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...